Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2011-07-12
2011-07-12
Richter, Johann R (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S464000, C424S486000
Reexamination Certificate
active
07976870
ABSTRACT:
Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.
REFERENCES:
patent: 4434153 (1984-02-01), Urquhart et al.
patent: 4690824 (1987-09-01), Powell et al.
patent: 4695467 (1987-09-01), Uemura et al.
patent: 4748023 (1988-05-01), Tamás et al.
patent: 4753801 (1988-06-01), Oren et al.
patent: 4786503 (1988-11-01), Edgren et al.
patent: 4839177 (1989-06-01), Colombo et al.
patent: 4851232 (1989-07-01), Urquhart et al.
patent: 4865849 (1989-09-01), Conte et al.
patent: 4871548 (1989-10-01), Edgren et al.
patent: 4910021 (1990-03-01), Davis et al.
patent: 5002772 (1991-03-01), Curatolo et al.
patent: 5007790 (1991-04-01), Shell
patent: 5064656 (1991-11-01), Gergely et al.
patent: 5085865 (1992-02-01), Nayak
patent: 5213808 (1993-05-01), Bar-Shalom et al.
patent: 5232704 (1993-08-01), Franz et al.
patent: 5382435 (1995-01-01), Geary et al.
patent: 5393765 (1995-02-01), Infeld et al.
patent: 5422123 (1995-06-01), Conte et al.
patent: 5425950 (1995-06-01), Dandiker et al.
patent: 5458887 (1995-10-01), Chen et al.
patent: 5458888 (1995-10-01), Chen
patent: 5464633 (1995-11-01), Conte et al.
patent: 5472708 (1995-12-01), Chen
patent: 5487901 (1996-01-01), Conte et al.
patent: 5508040 (1996-04-01), Chen
patent: 5549913 (1996-08-01), Colombo et al.
patent: 5582837 (1996-12-01), Shell
patent: 5609590 (1997-03-01), Herbig et al.
patent: 5626874 (1997-05-01), Conte et al.
patent: 5650169 (1997-07-01), Conte et al.
patent: 5651985 (1997-07-01), Penners et al.
patent: 5681583 (1997-10-01), Conte et al.
patent: 5688776 (1997-11-01), Bauer et al.
patent: 5736159 (1998-04-01), Chen et al.
patent: 5738874 (1998-04-01), Conte et al.
patent: 5780057 (1998-07-01), Conte et al.
patent: 5783212 (1998-07-01), Fassihi et al.
patent: 5811126 (1998-09-01), Krishnamurthy
patent: 5837379 (1998-11-01), Chen et al.
patent: 5840329 (1998-11-01), Bai
patent: 5840332 (1998-11-01), Lerner et al.
patent: 5861173 (1999-01-01), Nishioka et al.
patent: 5891474 (1999-04-01), Busetti et al.
patent: 5897874 (1999-04-01), Stevens et al.
patent: 5916595 (1999-06-01), Chen et al.
patent: 5945125 (1999-08-01), Kim
patent: 5972389 (1999-10-01), Shell et al.
patent: 6027748 (2000-02-01), Conte et al.
patent: 6033685 (2000-03-01), Qiu et al.
patent: 6093420 (2000-07-01), Baichwal
patent: 6120803 (2000-09-01), Wong et al.
patent: 6207197 (2001-03-01), Illum et al.
patent: 6221395 (2001-04-01), Maggi et al.
patent: 6248363 (2001-06-01), Patel et al.
patent: 6261601 (2001-07-01), Talwar et al.
patent: 6340475 (2002-01-01), Shell et al.
patent: 6368628 (2002-04-01), Seth
patent: 6451808 (2002-09-01), Cowles
patent: 6488962 (2002-12-01), Berner et al.
patent: 6562375 (2003-05-01), Sako et al.
patent: 2001/0018070 (2001-08-01), Shell et al.
patent: 2003/0091630 (2003-05-01), Louie-Helm et al.
patent: 2003/0133985 (2003-07-01), Louie-Helm et al.
patent: 2003/0152622 (2003-08-01), Louie-Helm et al.
patent: 2004/0156899 (2004-08-01), Louie-Helm et al.
patent: 2143500 (1995-08-01), None
patent: 0795324 (1997-09-01), None
patent: 0598309 (1998-01-01), None
patent: 1330829 (1973-09-01), None
patent: WO 9626717 (1996-09-01), None
patent: WO 96/32097 (1996-10-01), None
patent: WO 98/55107 (1998-12-01), None
patent: WO 00/23045 (2000-04-01), None
patent: WO 00/38650 (2000-07-01), None
patent: WO 01/32217 (2001-05-01), None
patent: WO 01/56544 (2001-08-01), None
patent: WO 01/97783 (2001-12-01), None
patent: WO 02/083687 (2002-10-01), None
CIPRO (ciprofloxacin hydrochloride) Tablets, CIPRO (ciprofloxacin) 5% and 10% Oral Suspension Drug Information Sheet, Aug. 20, 2000, pp. 1-9.
Ciprofloxicin. Datasheet [online]. MedSafe Information for Health Professionals, 2008 [retrieved on Jan. 14, 2010]. Retrieved from the Internet: <URL:http://www.medsafe.govt.nz/Profs/Datasheet/c/Ciproxinhocotic.htm>, pp. 1-10.
Prostatitis. Datasheet [online]. WebMD, 2005 [retrieved on Jan. 14, 2010]. Retrieved from the Internet: <URL:http://men.webmd.com/prostatitis>, pp. 1-4.
Ciprofloxacin Patient Information Sheet, Patient Information Sheet. [online]. Preferred Pharmaceuticals, 2000 [retrieved on Jul. 30, 2010]. Retrieved from the Internet: <URL: http://www.preferredpharmaceuticals.com/PEI/Ciprofloxacin.pdf.
Hou et al., “Gastric Retentive Dosage Forms: A Review,”Crit. Rev. Ther. Drug Carrier Syst.(2003) 20(6):461-497.
Louie-Helm et al., “Pharmacokinetics of Ciprofloxacin Gastric Retentive Tablets in Healthy Volunteers,”Control Release Soc. 28thAn. Meeting Proc.(2001) 6044.
Bloem et al., “A controlled trial of a slow-release form of furosemide in hypertension,” Curr. Ther. Res. (1981) 29:577-583.
Boles Ponto et al., “Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review,” (Parts I and II), Clin. Pharmacokinetics (1990) 18:381-471.
Gabr et al., “Formulation and evaluation of buffered floating furosemide delivery systems,” S.T.P. Pharma Sci. (2000) 10:181-186.
Iannuccelli et al., “PVP solid dispersions for the controlled release of furosemide from a floating multiple-dose unit system,” Drug Dev. Indus. Pharm. (2000) 26:595-603.
Kaniwa et al., “The bioavailability of flufenamic acid and its dissolution rate from capsules,” Intl. J. Clin. Pharmacol., Ther. Toxicol. (1983) 21:56-63.
Menon et al., “Development and evaluation of a monolithic floating dosage form for furosemide,” J. Pharmac. Sci. (1994) 83:239-245.
Uchino et al., “Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients,” J. Pharm. Dyn. (1983) 6:684-691.
Wakelkamp et al., “The influence of frusemide formulation on diuretic effect and efficiency,” J. Clin. Pharmacol. (1999) 48:361-366.
Abrahamsson et al. (1993), “Absorption, Gastrointestinal Transit, and Tablet Erosion of Felodipine Extended-Release (ER) Tablets,”Pharmaceutical Research10(5):709-714.
Apicella et al. (1993), “Poly(ethylene oxide) (PEO) and Different Molecular Weight PEO Blends Monolithic Devices for Drug Release,”Biomaterials14(2):83-90.
Columbo et al. (1990), “Drug Release Modulation by Physical Restrictions of Matrix Swelling,”International Journal of Pharmaceutics63:43-48.
Conte et al. (1996), “Modulation of the Dissolution Profiles from Geomatrix® Multi-Layer Matrix Tabletes Containing Drugs of Different Solubility,”Biomaterials17(9):889-896.
U.S. Appl. No. 09/425,491, filed Oct. 22, 1999, Shell et al.
U.S. Appl. No. 10/045,823, filed Oct. 25, 2001, Gusler et al.
U.S. Appl. No. 10/045,823, filed Nov. 6, 2001, Shell et al.
U.S. Appl. No. 10/066,146, filed Feb. 1, 2002, Lim et al.
U.S. Appl. No. 10/152,914, filed May 20, 2002, Fara et al.
Davis et al. (1986), “The Effect of Density on the Gastric Emptying of Single- and Multiple-Unit Dosage Forms,”Pharmaceutical Research3(4):208-213.
Deshpande et al. (1997), “Development of a Novel Controlled-Release System for Gastric Retention,”Pharmaceutical Research14(6):815-819.
Gusler et al. (Jun. 2001), “Pharmacokinetics of Metformin Gastric-Retentive Tablets in Healthy Volunteers,”The Journal of Clinical Pharmacology41(6):655-661.
Huber et al. (1966), “Utilization of Hydrophilic
Berner Bret
Louie-Helm Jenny
Shell John W.
Depomed Inc.
Harlocker Susan L.
Holt Andriae M
Mohr Judy M.
Richter Johann R
LandOfFree
Gastric retentive oral dosage form with restricted drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gastric retentive oral dosage form with restricted drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastric retentive oral dosage form with restricted drug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641346